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Preference, satisfaction and critical errors with Genuair and
Breezhaler inhalers in patients with COPD: a randomised,
cross-over, multicentre study
Sergi Pascual1, Jan Feimer2, Anthony De Soyza3,4, Jaume Sauleda Roig5,6,7, John Haughney8, Laura Padullés9, Beatriz Seoane10,11,
Ludmyla Rekeda12, Anna Ribera10,11 and Henry Chrystyn13
BACKGROUND: The speciﬁc attributes of inhaler devices can inﬂuence patient use, satisfaction and treatment compliance, and may
ultimately impact on clinical outcomes in patients with chronic obstructive pulmonary disease (COPD).
AIMS: To assess patient preference, satisfaction and critical inhaler technique errors with Genuair (a multidose inhaler) and
Breezhaler (a single-dose inhaler) after 2 weeks of daily use.
METHODS: Patients with COPD and moderate to severe airﬂow obstruction were randomised in a cross-over, open-label,
multicentre study to consecutive once-daily inhalations of placebo via Genuair and Breezhaler, in addition to current COPD
medication. The primary end point was the proportion of patients who preferred Genuair versus Breezhaler after 2 weeks (Patient
Satisfaction and Preference Questionnaire). Other end points included overall satisfaction and correct use of the inhalers after
2 weeks, and willingness to continue with each device.
RESULTS: Of the 128 patients enrolled, 127 were included in the safety population (male n= 91; mean age 67.6 years). Of the 110 of
the 123 patients in the intent-to-treat population who indicated an inhaler preference, statistically signiﬁcantly more patients
preferred Genuair than Breezhaler (72.7 vs. 27.3%; Po0.001). Mean overall satisfaction scores were also greater for Genuair than for
Breezhaler (5.9 vs. 5.3, respectively; Po0.001). After 2 weeks, there was no statistically signiﬁcant difference in the number of
patients who made ⩾ 1 critical inhaler technique error with Breezhaler than with Genuair (7.3 vs. 3.3%, respectively).
CONCLUSIONS: Patient overall preference and satisfaction was signiﬁcantly higher with Genuair compared with Breezhaler. The
proportion of patients making critical inhaler technique errors was low with Genuair and Breezhaler.
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INTRODUCTION
There are numerous inhaler devices available for the delivery of
bronchodilator treatment in patients with chronic obstructive
pulmonary disease (COPD): for example, dry-powder inhalers
(DPIs), pressurised metered-dose inhalers, soft mist inhalers and
nebulisers.1–3 Each inhaler has advantages and disadvantages
that may impact on a patient’s use, satisfaction and compliance
with therapy, and ultimately affect clinical outcomes.4,5 Choosing
the most appropriate inhaler for a patient is likely to positively
inﬂuence their attitude to COPD, improve adherence to therapy
and, consequently, have therapeutic beneﬁts.4 It is therefore
important that each patient be prescribed an inhaler device that
they are both willing and able to use.6 This may be particularly
true in elderly patients, who may have cognitive
and/or physical issues that make inhaler use particularly
challenging.7
Despite the importance of inhaled therapies in the manage-
ment of COPD, incorrect inhalation technique is common among
patients with COPD8–10 and is thought to be a key reason for
reduced disease control in COPD.11,12 Issues relating to incorrect
inhaler technique may also be worsened because many patients
with COPD require multiple inhaled therapies (e.g., short-acting
bronchodilators, long-acting bronchodilators, inhaled corticoster-
oids), which are often administered via separate inhalers that
require distinct inhalation techniques for optimal use.5,8,13
Ensuring that patients with COPD always use the correct
technique is key to achieving maximal beneﬁt from inhaled
therapies.14
The speciﬁc attributes of an inhaler device that may help to
promote adherence and use of the correct technique include
convenience, efﬁciency and ease of use, with simple instructions
and minimal potential for errors.3 Genuair (Pressair in the United
States; AstraZeneca, Mölndal, Sweden; registered trademarks of
AstraZeneca A.B., Mölndal, Sweden, for use within the USA as
Pressair and Genuair within all other licensed territories), is a
novel, multidose, breath-actuated DPI for the delivery of
aclidinium bromide (a long-acting muscarinic antagonist) either
alone or in combination with formoterol fumarate (a long-acting
β2-agonist), indicated as maintenance bronchodilator treatment in
COPD.15–17 The objective of this study was to assess patient
preference, satisfaction and critical inhaler technique errors after a
2-week period of inhaling placebo via Genuair and Breezhaler
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(Novartis, A.G., Basel, Switzerland). In contrast with Genuair,
Breezhaler is a single-dose, breath-actuated DPI that works
through the release of dry powder from a pierced gelatin capsule.
The patient is required to load each capsule into the device before
inhalation of a dose. Breezhaler was chosen as the comparator
device in this study, as both inhalers are used in patients with
COPD and contain a long-acting bronchodilator.
METHODS
Study design and patients
This was a randomised, cross-over, open-label study performed in ﬁve
centres in Germany, Spain and the United Kingdom between July and
October 2013 (ClinicalTrials.gov registration: NCT01915784). The study was
conducted in accordance with the ethical principles of the Declaration of
Helsinki and the International Conference on Harmonisation Good Clinical
Practice guidelines. The study complied with all applicable local regulatory
requirements and was approved by the relevant local independent ethics
committees. Each patient provided written informed consent prior to
participation in the study.
Male or female patients were eligible for inclusion in the study if they
were aged ⩾ 40 years with moderate to severe stable COPD according to
the GOLD classiﬁcations (post-bronchodilator forced expiratory volume in
1 second (FEV1) ⩾ 30% but o80% of the predicted normal value, and post-
bronchodilator FEV1/forced vital capacity o0.7).18 Patients must have
been naive to both inhaler devices for ⩾ 2 years. Key exclusion criteria
included the presence of clinically signiﬁcant, uncontrolled chronic
diseases (particularly those affecting coordination and/or motor system
and other chronic respiratory diseases) and/or a COPD exacerbation within
6 weeks of Visit 1, or within 3 months if hospitalisation was required.
The study consisted of two scheduled visits (Visits 1 and 2) with a
2-week period in-between (Figure 1). At Visit 1, patients were randomised
(1:1) using a computer-generated randomisation schedule to inhale
placebo via both Genuair and Breezhaler in one of two treatment
sequences: Genuair ﬁrst, Breezhaler second or Breezhaler ﬁrst, Genuair
second. At this visit, trainers demonstrated to patients the correct use of
both inhalers according to the sequence in which the patient was
instructed to use them. Following the demonstration, patients read the
device instructions and demonstrated their use of the device until
successful; a maximum of ﬁve attempts were permitted. Patients who
failed to use either inhaler correctly after ﬁve attempts were discontinued
from the study. After Visit 1, patients used both inhaler devices, containing
placebo, once daily for 2 weeks. After 2 weeks (Visit 2), the trainers
assessed patients’ preference, satisfaction and correct use of both inhalers,
as well as their willingness to continue with each device and compliance
with the inhaler devices. To assess inhaler technique, without further
training, patients demonstrated use of both inhalers (in the same order as
Visit 1) until successful, with a maximum of ﬁve attempts with each inhaler.
Patients continued with their usual medications (including those for
COPD) throughout the study; this could include use of inhalers other than
those being investigated in the study. The Genuair and Breezhaler devices
contained only the lactose carrier (placebo).
Assessments
Patients completed the multi-item Patient Satisfaction and Preference
Questionnaire (PASAPQ)19 to measure their satisfaction and preference for
both inhalers. This is a self-administered, 16-item measure of respiratory
inhalation device satisfaction and preference for patients with asthma and
COPD. It includes 13 satisfaction items measured on a Likert-type response
scale from 1 (very dissatisﬁed) to 7 (very satisﬁed); these are grouped into
two domains (performance and convenience) and constitute the total
score (Supplementary Table 1). Each individual item contributes equally to
the total score. The PASAPQ also contains an overall satisfaction question
(measured on the 1–7 scale, with a score of 7 representing the highest
level of satisfaction), a preference item (selection between devices or ‘no
preference’) and a question on willingness to continue using the device
(measured on a scale of 0 (not willing) to 100 (deﬁnitely willing)). During
validation of the PASAPQ, the threshold for clinical relevance was
estimated (the minimally important difference, MID). To achieve a small
or medium effect difference in the performance domain required a
difference of 4 or 10 points, respectively. For both the convenience domain
and total score, the small or medium effect difference was estimated to be
3 or 8 points, respectively.19
The correct use of the inhaler devices was assessed by evaluating errors
made by patients at Visits 1 and 2. Errors were categorised as critical or
non-critical and were dependent on the individual inhaler (Supplementary
Table 2). Critical errors were deﬁned as those that compromised the
potential beneﬁt of the treatment, such as impeding drug deposition in
the lungs or the delivery of an insufﬁcient dose, while non-critical errors
did not compromise the potential beneﬁt of the treatment.
At Visit 2, patients’ compliance was assessed using the dose counter for
Genuair and the number of capsules used and unused for Breezhaler
(Supplementary Material). Compliance was deﬁned as 10 out of 14
doses used.
The primary efﬁcacy end point was the proportion of patients who
preferred Genuair versus Breezhaler overall at Visit 2. The secondary end
points were overall satisfaction with the inhaler device and critical inhaler
technique errors at Visit 2. Additional efﬁcacy variables included
satisfaction with each of the individual performance and convenience
attributes and willingness to continue using each inhaler.
Statistical analyses
Patients’ preference for Genuair at Visit 2 was analysed using the
Mainland–Gart’s test. In addition, a sensitivity analysis using Prescott’s
test was carried out, which also included all patients who indicated ‘no
preference’ for either inhaler. Mean PASAPQ total score, performance
score, convenience score and score for individual attributes of each inhaler
were analysed using an analysis of variance model for cross-over designs,
including sequence, period and inhaler type as ﬁxed factors and patient
within sequence as a random effect. The differences between devices
(estimated by differences between least square means) and standard error
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Figure 1. Study design.
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(s.e.) are also presented. The proportion of patients making ⩾ 1 critical
error using each inhaler device at Visit 2 was analysed using Prescott’s test.
All analyses were performed on the intent-to-treat population (all
randomised patients who used both inhaler devices at least once and
answered the preference question of the PASAPQ).
A minimum sample size of 120 patients was required to have 90%
power to detect a preference of 65 versus 35% in favour of one of the
inhaler devices (assuming 5% of patients expressed no preference or
discontinued the study), with a two-sided test at the 5% signiﬁcance level.
RESULTS
Patients
A total of 128 patients were enrolled and randomised in the study.
Of these, 127 patients were included in the safety population (all
randomised patients who used both inhaler devices at least once)
and 123 in the intent-to-treat population; 124 patients completed
the study (Figure 2). No patient was discontinued from the study
for failing to demonstrate correct use of the study inhaler devices
after ﬁve attempts at Visit 1. Of the 128 patients randomised, 98
(76.6%) and 96 (75.0%) achieved correct use of the Genuair and
Breezhaler inhalers, respectively, at the ﬁrst attempt at Visit 1; for
both inhalers, ﬁve attempts were required for 100% of patients to
achieve correct inhaler technique.
Demographics and baseline characteristics for the safety
population are shown in Table 1. The majority of patients were
male (n= 91 (71.7%)); mean age was 67.6 years and mean
predicted FEV1 was 49.3%. The most commonly used concomitant
inhaler device was the HandiHaler, used by 75% of patients
(Table 2). Overall compliance was equally high for both Genuair
and Breezhaler (95.3 vs. 94.5%, respectively; Supplementary
Material).
Device preference
110 of the 123 patients in the intent-to-treat population who
indicated a preference for either inhaler after 2 weeks, a
statistically signiﬁcantly higher proportion preferred Genuair to
Breezhaler (72.7 vs. 27.3%, respectively; Po0.001). Sensitivity
analysis using Prescott’s test to assess the inﬂuence of patients
who indicated ‘no preference’ (13 patients, 10.6%) was consistent
in showing that more patients preferred Genuair to Breezhaler
(65.0 vs. 24.4%, respectively; Po0.001).
Device satisfaction
The overall satisfaction score for Genuair at Visit 2 was statistically
signiﬁcantly greater compared with Breezhaler (mean (s.e.), 5.9
(0.15) vs. 5.3 (0.15), respectively; Po0.001). When the individual
attributes of each inhaler were considered, patients were
statistically signiﬁcantly more satisﬁed with Genuair compared
with Breezhaler for ﬁve of the seven performance attributes
(Figure 3a) and for three of the six convenience attributes
(Figure 3b).
Genuair was also statistically superior to Breezhaler in terms of
patient satisfaction measured by total score (mean (s.e.), 80.5
(1.73) vs. 75.5 (1.73), respectively; P= 0.002), overall performance
score (80.5 (1.95) vs. 73.7 (1.95), respectively; P= 0.002) and
convenience score (80.6 (1.70) vs. 77.4 (1.70), respectively;
P= 0.022) of the PASAPQ. The MIDs between the inhalers in total
score (5 points) and performance score (6.8 points) exceeded the
small effect difference but did not achieve the medium effect
difference. The difference in the convenience score (3.2 points)
represented a small effect difference.
When patients were asked to indicate their willingness to
continue using each inhaler, on a scale of 0–100, the mean score
was statistically signiﬁcantly greater for Genuair than Breezhaler
(mean (s.e.), 79.6 (2.60) vs. 63.6 (2.60), respectively; Po0.0001),
indicating a greater willingness to continue using Genuair. The
mean difference in score (s.e.) between Genuair and Breezhaler
was 16.0 (3.68; Po0.0001).
Critical errors
After 2 weeks' use of Genuair and Breezhaler, fewer patients made
critical errors at Visit 2, compared with Visit 1 (Visit 1, n= 28
(22.8%) and n= 30 (24.4%); Visit 2, n= 4 (3.3%) and n= 9 (7.3%),
respectively). At Visit 2, there was no statistically signiﬁcant
difference in the number of patients who made ⩾ 1 critical inhaler
technique error with only Genuair or only Breezhaler.
At Visit 2, 15 patients made a total of 41 inhaler technique
errors, 31 of which occurred at the ﬁrst attempt. The numbers of
errors at each stage of inhaler use are shown in Table 3. At Visit 2,
aHyperhidrosis, lip blister, mood swings and oral discomfort.
bDid not meet FEV1 screening criteria.
FEV1,
 
forced expiratory volume in 1 second; ITT, intent-to-treat.
Completed
124 (96.9%)
Safety population: 127 (99.2%)
ITT population: 123 (96.1%)
Discontinued from study: 4 (3.1%)
 
aAdverse event: 1 (0.8%)
 Patient’s decision (unrelated to adverse event): 2 (1.6%)
 
bOther: 1 (0.8%)
128 patients randomised
Figure 2. Patient disposition.
Table 1. Demographics and baseline characteristics (safety
population)
Variable N= 127
Age, mean (s.d.), years 67.6 (8.0)
Gender male, n (%) 91 (71.7)
Duration of COPD, mean (s.d.), years 8.5 (8.1)
Predicted FEV1,
a mean (s.d.), % 49.3 (13.0)
Abbreviations: COPD, chronic obstructive pulmonary disease; FEV1, forced
expiratory volume in 1 second; s.d., standard deviation.
aN= 126.
Table 2. Concomitant inhaler device use during the study (safety
population)
Inhaler,
n (%)
Genuair/Breezhaler
(N= 64)
Breezhaler/Genuair
(N= 63)
Total
N= 127
Turbuhaler 23 (35.9) 17 (27.0) 40 (31.5)
Diskus 17 (26.6) 13 (20.6) 30 (23.6)
Respimat 8 (12.5) 7 (11.1) 15 (11.8)
pMDI 26 (40.6) 37 (58.7) 63 (49.6)
HandiHaler 48 (75.0) 47 (74.6) 95 (74.8)
Others 21 (32.8) 21 (33.3) 42 (33.1)
Abbreviation: pMDI, pressurised metered-dose inhaler.
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the most common critical errors (⩾2 patients) occurring on the
ﬁrst attempt with Breezhaler were: not inhaling strongly enough
to hear the buzzing that indicates the capsule is spinning around
the chamber (n= 4 (3.3%)); the capsule not spinning around in the
chamber when inhaling (n= 2 (1.6%)); and not repeating the
inhalation due to powder residue in the capsule and removal of
the capsule immediately without checking for the presence of
powder residue (n= 2 (1.6%)). One patient made errors in all three
of these steps of Breezhaler use. The only critical error made
by ⩾ 2 patients on the ﬁrst attempt of Visit 2 with Genuair was
not exhaling before introducing the mouthpiece into the mouth
(n= 2 (1.6%)).
DISCUSSION
Main ﬁndings
This randomised, cross-over study was designed to assess
patients’ preference for overall satisfaction with and correct use
of Genuair compared with Breezhaler after 2 weeks of daily use.
The primary end point showed that signiﬁcantly more patients
with COPD preferred Genuair over Breezhaler. Furthermore,
overall satisfaction was statistically signiﬁcantly higher and
patients were more willing to continue using Genuair than
Breezhaler. No statistically signiﬁcant difference was found
between Genuair and Breezhaler in the proportion of patients
who made critical inhalation technique errors during use.
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Figure 3. Mean satisfaction scores for attributes in the performance (a) and convenience (b) domains of the PASAPQ after two weeks of daily
practice (intent-to-treat population; N= 123).
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Interpretation of ﬁndings in relation to previously published work
The PASAPQ has been validated in patients with asthma, COPD
and in patients with overlapping features of asthma and COPD.19
Post-validation, the questionnaire has been used in other inhaler
comparison studies including a 12-week assessment of preference
for the Respimat Soft Mist inhaler versus a multidose, preﬁlled, DPI
in patients with asthma.20 In the study, both inhalers contained
budesonide, and results revealed a preference for Respimat over
the DPI. In a 48-week study comparing patient satisfaction using
the Respimat inhaler and a metered-dose inhaler, both containing
ipratropium bromide/albuterol in patients with COPD, the PASAPQ
performance score was signiﬁcantly higher with the Respimat
inhaler and performance score MIDs were maintained at all
treatment visits.21
Inhaler attributes rated as being ‘very important’ by patients
with COPD are those associated with simplicity and ease of use.3,22
In the van der Palen3 study, among 105 patients with COPD,
satisfaction with Genuair was signiﬁcantly superior to the
HandiHaler DPI device. In this study, although patients were not
asked to rate the attributes of each inhaler, Genuair was
statistically superior to Breezhaler in terms of satisfaction, with a
number of attributes associated with those aspects deemed to be
important to patients, including ease of inhaling a dose, ease of
using the inhaler and ease of holding during use.
In this study, it was not possible to compare patient satisfaction
scores with measures of clinical outcomes because both inhalers
contained placebo. However, previous real-world studies have
shown signiﬁcant correlations between patients’ satisfaction with
their inhaler and reduced exacerbation frequency, improved
treatment compliance and improved health-related quality of life
in patients with both asthma and COPD.8,23 Furthermore, during
validation of the PASAPQ, Kozma et al.19 proposed thresholds
above which differences between the devices could be consid-
ered clinically meaningful (small and medium effect differences).
In this study, Genuair was statistically superior to Breezhaler in
terms of patient satisfaction measured by total score, and
performance and convenience scores, with differences between
the inhalers in convenience score (3.2 points) representing a small
effect difference and differences in total score (5 points) and
performance score (6.8 points) exceeding the small effect
difference. Kozma et al.19 acknowledge the challenges inherent
in applying the concept of an MID to satisfaction measures given
that they are more dependent on the devices being investigated
and the population being studied than is the case with quality-of-
life measures such as the EQ-5D.19 The higher level of patient
satisfaction for Genuair over Breezhaler reported in this study may
lead to improved clinical outcomes for patients using Genuair
compared with Breezhaler in a real-world setting. We acknowl-
edge, however, that in this 2-week study, compliance, which is
also associated with improved clinical outcomes,8,23 was equally
high for both inhalers.
Evidence suggests that up to half of patients using inhalers
have errors in their inhalation technique and that most patients
may not have their technique monitored by a clinician.9,24 The
overall incidence of critical errors reported in this study was low
for both inhalers. The number of critical errors with Genuair was
similar to that previously reported in a randomised, cross-over
study comparing Genuair with HandiHaler.3 Breezhaler and
HandiHaler have a similar mechanism of action (capsule piercing
system) and therefore a similar number of errors might be
expected when assessing the two inhalers. Although there was a
numerically lower incidence of critical errors with Genuair than
Breezhaler in this study, there was no statistically signiﬁcant
difference between Genuair and Breezhaler in the number of
critical errors at Visit 2. This result differs from the signiﬁcantly
lower incidence of errors previously reported for Genuair
compared with HandiHaler.3 However, a high proportion of
patients (75%) were using HandiHaler for the administration of
concomitant COPD medication during our current study. There-
fore, although there are a greater number of potential errors
associated with Breezhaler compared with Genuair (due to the
greater number of steps in the inhalation process), familiarity with
HandiHaler may have improved Breezhaler technique and resulted
in no overall difference in the number of errors observed
compared with Genuair. The most common critical errors reported
for Breezhaler (not inhaling strongly enough; the capsule not
spinning during inhalation; and not repeating inhalation or
checking for powder residue in the capsule), occurring in six
patients in total, would be anticipated to mean the patient did not
receive the intended dose of medication, potentially leading to
reduced disease control.
Strengths and limitations of this study
A strength of the present study is that the inhaler devices
contained placebo rather than an active ingredient, while patients
continued with their normal COPD medication. This approach
minimises bias and allows a true reﬂection of device preference
without the inﬂuence of treatment on patients’ airﬂow obstruc-
tion. During validation of the PASAPQ, attempts were made to
estimate thresholds above which differences between inhalers
could be considered clinically relevant (the MID). It remains to be
determined whether the concept of an MID is relevant to a study
comparing two inhalers, both containing placebo. It was also
encouraging that more patients had an overall preference for
Genuair compared with Breezhaler, regardless of whether patients
responded with ‘no preference’. Further strengths of this study are
that it was conducted over a wide geographical area, by a range of
health care professionals from different backgrounds, and that
assessments were made after 2 weeks of home use, which reﬂects
real-life conditions of inhaler training and use. However, it is
acknowledged that the time interval between training and
assessment was relatively short. The 2-week time interval was
considered sufﬁcient to evaluate preference and correct inhaler
use while also minimising inhaler burden given that patients
continued their usual medications (including those for COPD)
throughout the study. As inhaler errors occurred in this study
despite the short time interval, the potential for error rate
increasing over time should be investigated in the future. It is also
acknowledged that the sequential use of different inhaler devices
may not reﬂect real-life clinical practice. Genuair is currently used
for the administration of aclidinium bromide, or aclidinium
bromide plus formoterol fumarate, which requires twice-daily
administration.15–17 However, given the high level of patient
satisfaction with Genuair and willingness to continue use reported
in this study, twice-daily use of this inhaler is unlikely to affect
compliance.
Table 3. Number of inhaler technique errors at Visit 2, by error
categorya (ITT population; N= 123)
Error category Genuair Breezhaler
Critical errors prior to inhalation 0 0
Critical errors preparing for inhalation 2 3
Critical errors during inhalation 5 10
Critical errors after inhalation NA 3
Non-critical errors 14 4
Some patients may have made errors with both inhalers and 41 error
within each error category.
Abbreviations: ITT, intent-to-treat; NA, not applicable.
aFull list of errors within each category can be found in Supplementary
Table 2.
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Implications for future research, policy and practice
The ﬁndings of this study indicate a preference for Genuair over
Breezhaler among patients with COPD and provide a useful basis
for further understanding of patient satisfaction with Genuair.
Further investigation of the nature of critical errors may expand
our knowledge of ways to improve patient inhaler technique. This
is particularly pertinent in light of evidence suggesting that
helping patients manage their condition and gain the maximum
beneﬁt from their inhaler may improve clinical outcomes.4 A study
comparing Genuair with other inhalers over a longer time period
may be useful to assess patient preference, satisfaction and
compliance and evaluate the incidence of errors over the long
term. It would also be interesting to evaluate patient satisfaction
and compliance with Genuair in relation to clinical outcomes.
Conclusions
In this study of patients with COPD, preference, satisfaction and
willingness to continue using the inhaler were statistically
signiﬁcantly higher with Genuair compared with Breezhaler. The
proportion of patients who made critical errors was low with both
inhalers. Ensuring that patients are able to use their inhaler device
correctly is likely to be important for increasing patient satisfaction
and, consequently, improving treatment compliance and clinical
outcomes in COPD.
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